Roth Capital Expects Weaker Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Investment analysts at Roth Capital dropped their Q2 2025 earnings estimates for Sensus Healthcare in a research note issued to investors on Thursday, May 15th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $0.03 per share for the quarter, down from their prior forecast of $0.08. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.32 per share. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.18 EPS, FY2026 earnings at $0.19 EPS and FY2027 earnings at $0.22 EPS.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The company had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million.

A number of other equities research analysts have also recently issued reports on SRTS. Lake Street Capital reduced their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th.

Sensus Healthcare Stock Performance

Shares of Sensus Healthcare stock opened at $4.46 on Monday. The firm has a 50-day moving average of $4.61 and a 200-day moving average of $6.12. The stock has a market cap of $73.57 million, a PE ratio of 11.15 and a beta of 1.30. Sensus Healthcare has a 52-week low of $4.01 and a 52-week high of $9.33.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the company. Trexquant Investment LP acquired a new position in Sensus Healthcare during the first quarter worth about $93,000. Meros Investment Management LP bought a new stake in Sensus Healthcare in the first quarter valued at approximately $419,000. American Century Companies Inc. boosted its holdings in Sensus Healthcare by 12.7% in the first quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock valued at $106,000 after acquiring an additional 2,520 shares during the last quarter. Pacific Ridge Capital Partners LLC bought a new stake in Sensus Healthcare in the first quarter valued at approximately $542,000. Finally, IFP Advisors Inc grew its position in shares of Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock worth $89,000 after buying an additional 5,100 shares during the period. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.